Chronic Myelogenous Leukaemia Treatment Market

Table of Content

1. Introduction
   • Definition of Chronic Myelogenous Leukaemia Treatment Market
   • Scope of the Report
2. Methodology
   • Executive Summary
   • Market Overview
   • Market Definition and Segmentation
3. Market Dynamics
   • Drivers
   • Restraints
   • Opportunities
   • Porter's Five Forces Analysis
   • PESTEL Analysis
4. Chronic Myelogenous Leukaemia Treatment Market, By Treatment
   • Targeted therapy
   • Chemotherapy
5. Chronic Myelogenous Leukaemia Treatment Market, By Route Of Administration
   • Oral
   • Parenteral
6. Chronic Myelogenous Leukaemia Treatment Market, By Product
   • Tablets
   • Capsules
   • Injections
   • Others
7. Chronic Myelogenous Leukaemia Treatment Market, By Distribution Channels
   • Online
   • Offline
8. Chronic Myelogenous Leukaemia Treatment Market, By End-User
   • Hospital pharmacies
   • Online pharmacies
   • Retail pharmacies
9. Chronic Myelogenous Leukaemia Treatment Market, By Geography
   • North America
     • United States
     • Canada
   • Europe
     • United Kingdom
     • Germany
     • France
     • Spain
     • Italy
     • Rest of Europe
   • Asia-Pacific
     • China
     • Japan
     • India
     • South Korea
     • Australia
     • Rest of Asia-Pacific
   • Latin America
     • Brazil
     • Mexico
     • Rest of Latin America
   • Middle East & Africa
     • Saudi Arabia
     • United Arab Emirates
     • South Africa
     • Rest of Middle East & Africa
10. Competitive Landscape
11. Company Profiles
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Product Portfolio and Description
      • Key Highlights
      • Financial Overview
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Sanofi
    • Merck & Co. Inc
    • Innovent Biologics, Inc.
    • Hikma Pharmaceuticals LLC
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
12. Conclusion and Future Outlook
13. Appendix
    • Research Methodology
    • About the Pharmanucleus
14. Disclaimer